JAJyotirmoi Aich

Jyotirmoi Aich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jyotirmoi Aich has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach

    by Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich

    Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of total diabetes mellitus cases all over the world. Obesity and lack of balance between energy intake and energy expenditure are closely linked to T2DM. Initial pharmaceutical treatment and lifestyle interventions can at times lead to remission but usually help alleviate it to a certain extent and the condition remains, thus, recurrent with the patient being permanently pharmaco-dependent. Mesenchymal stromal cells (MSCs) are multipotent, self-renewing cells with the ability to secrete a variety of biological factors that can help restore and repair injured tissues. MSC-derived exosomes possess these properties of the original stem cells and are potentially able to confer superior effects due to advanced cell-to-cell signaling and the presence of stem cell-specific miRNAs. On the other hand, the repository of antidiabetic agents is constantly updated with novel T2DM disease-modifying drugs, with higher efficacy and increasingly convenient delivery protocols. Delving deeply, this review details the latest progress and ongoing studies related to the amalgamation of stem cells and antidiabetic drugs, establishing how this harmonized approach can exert superior effects in the management and potential reversal of T2DM.


  • Dietary Polyphenols in Bacterial and Fungal Infections

    by Veda Joshi, Swarangi Tambat, Mustansir Bhori, Jyotirmoi Aich, Kanchanlata Tungare

    The ever-increasing global disease burden continually draws the attention of the scientific community to novel therapeutics and their promising beneficial effects. Profound results of many studies have confirmed the superiority and prolificity of natural compounds over conventional synthetic drugs. The scientific endeavors to discover the various health benefits of dietary polyphenols have investigated its potent effects in many diseases and conditions, as opposed to most of the artificially synthesized drugs that bring about a specific effect. Recent efforts in understanding the plausible equivalents of drug candidates have uncovered the phenomenal properties and diverse varieties of dietary polyphenols that are available in abundance in our daily diet. This chapter elucidates the different classes, structural and physiological properties of dietary polyphenols with justification for their diverse nature and therapeutic effects. Current research on polyphenols has revealed their antibacterial and antifungal properties much to the rescue of mankind. The omnipresence of both the pathogens, complex structures, high virulence, and intricate mechanisms of infection makes it difficult to design an ideal multi-faceted drug. Furthermore, the acquisition of drug resistance and genetic mutations helps these pathogens to escape the deleterious effects of several drugs. Unlike conventional drug formulations, polyphenols act through numerous mechanisms by targeting multiple cellular machinery and interfering in the major metabolic pathways of these microbes. Polyphenols, by virtue of their heterogeneous nature of synergistic and immunomodulatory mechanisms, qualify as among the most suitable nutraceuticals that have immense potential to act against infections.

  • Anti-Cancer Phytopharmaceuticals

    by Priyanka Mudaliar, Apoorva Jagannath Nalawade, Priyamvada Arte, Akanksha Dhuliya, Deepak Iyer, Kanchanlata Tungare, Mustansir Bhori, Jyotirmoi Aich

    Cancer is among the world’s most severe health concerns, with escalating prevalence. Though there has been remarkable evolvement in the treatment and management of cancer growth, there are still flaws and space for improvements. The need for cytotoxic agents is still an important field of research in the development of current anticancer medications. Many novel marketed cancer treatments have been either derived from natural sources, through structural alteration of native compounds, or by the synthesis of new compounds based on a natural component as a model. Exploration and harnessing nature, particularly for the discovery of new anticancer medicines, is a boon in the search for new and better pharmaceuticals. Herbs continue to be an important source of many clinically effective anticancer drugs used around the world, and many of them have been identified and are in clinical trials. The current chapter covers the most recent findings in cancer prevention and treatment using phytochemical constituents from plant sources, with a focus on plant-derived organic chemicals that have shown great potential as anticancer agents in recent years, with their respective mechanism of action, development challenges and opportunities.

  • Open Access

    One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

    by Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shine Devarajan, Jyotirmoi Aich

    Background: Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world. Current treatment modalities are associated with severe toxicities and lower efficiency. Hence, there is an unmet need for the development of novel drugs that can be used as adjuvants in breast chemotherapy. One of the strategies used to overcome this problem and that has received scientific coverage over the years is ‘Drug Repurposing’. For this purpose, a list of 5-aminosalicylates drugs were evaluated for their drug repurposing potential in breast cancer. Mesalamine, sulfasalazine, balsalazide, and olsalazine were docked with high expression signatures in cancer cells such as EGFR (epidermal growth factor receptor), ERα (Estrogen Receptor alpha), Aromatase, mTOR (mammalian target of rapamycin), ALOX5 (Arachidonate 5-lipoxygenase), and Topoisomerase II. Results: Docking analysis revealed that the selected ligands (drug) exhibited good binding affinity for all receptors. Based on the specificity with receptors, mesalamine was further selected for in vitro functional validation in a breast cancer cell line. Cell-based cytotoxicity assay in MCF-7 (Michigan Cancer Foundation-7) cells demonstrated the anticancer potential of mesalamine in breast cancer with IC-50 (Inhibitory Concentration) of 6.358 µM. Conclusions: Significant morphological alterations were observed in breast cells treated with mesalamine. Further studies are warranted to explore the anticancer effect of mesalamine in breast cancer and its role in combination therapies to be used as an adjuvant in chemotherapy.


  • Open Access

    Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a review

    by Shafina Siddiqui, Ankita Jaywant Deshmukh, Priyanka Mudaliar, Apoorva Jagannath Nalawade, Deepak Iyer, Jyotirmoi Aich

    While majority of the current treatment approaches for cancer remain expensive and are associated with several side effects, development of new treatment modalities takes a significant period of research, time, and expenditure. An alternative novel approach is drug repurposing that focuses on finding new applications for the previously clinically approved drugs. The process of drug repurposing has also been facilitated by current advances in the field of proteomics, genomics, and information computational biology. This approach not only provides cheaper, effective, and potentially safer drugs with less side effects but also increases the processing pace of drug development. In this review, we wish to highlight some recent developments in the area of drug repurposing in cancer with a specific focus on the repurposing potential of anti-psychotic, anti-inflammatory and anti-viral drugs, anti-diabetic, antibacterial, and anti-fungal drugs.


  • Therapeutic potential of autophagy activators and inhibitors in lung and breast cancer- a review

    by Priyanka Mudaliar, Apoorva Nalawade, Shine Devarajan, Jyotirmoi Aich

    Autophagy is a cellular process that eliminates damaged components of cytoplasm via the lysosome. Autophagy supports cells and tissues to remain healthy by recycling old or damaged cellular organelles and proteins with new ones. The breakdown products that follow are directed into cellular metabolism, where they are utilized to produce energy as well as for maintaining homeostasis and stability of the genome. In many cancers, autophagy modulation carries out a dual role in cancer development and suppression. Autophagy suppresses the proliferation of cancer cells by bringing about cell death and limiting cancer cell development, although it also promotes tumorigenesis by encouraging cancer cell growth and formation. Nevertheless, autophagy’s implication in cancer remains a paradox. While several autophagy activators, and inhibitors, such as SAH-EJ2, Gefitinib, Ampelopsin hydroxychloroquine and chloroquine, are utilized to regulate autophagy in chemoprevention, the exact intrinsic system of autophagy in cancer deserves further investigation. Despite improved treatment regimens, the incidence rate of both breast and lung cancer has grown, as has the number of recurrence cases. Hence, this review offers a wide overview of autophagy’s underlying role in lung and breast cancer, particularly focusing on the various autophagy activators and inhibitors in both cancers, as well as the use of various organic compounds, regular drugs, and natural products in cancer prevention and treatment.


  • Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery andin vitroinsight

    by Dayanand Swami, Priyanka Mudaliar, Yash Shrinivas Bichu, Vishal Kumar Sahu, Shine Devarajan, Soumya Basu, Jyotirmoi Aich

    HIV-protease inhibitor Ritonavir (RTV) is a clinical-stage drug. We exhibit here the synergistic effect of RTV coupled with cisplatin as potential combination therapy for treatment of cervical cancer. Knowledge about the interaction of RTV with the high-expression signatures in cancer is limited. Therefore, we utilized computational techniques to understand and assess the drug-binding affinity and drug-target interaction of RTV with these altered protein signatures. Computational studies revealed the potential interaction ability of RTV along with few other HIV protease inhibitors against these altered cancer targets. All targets exhibited good affinity towards RTV and the highest affinity was exhibited by CYP450 3A4, PDGFR and ALK. RTV established stable interaction with PDGFR and molecular dynamics simulation confirms their frequent interaction for 300 ns. Control docking of PDGFR with standard PDGFR inhibitor exhibited lower binding affinity when compared with RTV-PDGFR complex. In search of drugs as a part of combination therapy to reduce side effects of Cisplatin, this paper further evaluated the effect of combination of RTV and Cisplatin in cervical cancer cells. We propose several combination models that combines anti-viral drug RTV and standard chemotherapeutic agent, Cisplatin to be synergistic with CI value ranging from of 0.01 to 1.14. These observations suggest that anti-viral compound (RTV) could act synergistically with Cisplatin for cervical cancer therapy. However, further studies are warranted to investigate the combinatorial mode of action of RTV and Cisplatin on different molecular pathways to have a translational outcome in cervical cancer. Communicated by Ramaswamy H. Sarma


  • Drug repurposing—an emerging strategy in cancer therapeutics

    by Khadija Shahab Turabi, Ankita Deshmukh, Sayan Paul, Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shreelekha Naikar, Shine Devarajan, Soumya Basu, Manash K. Paul, et al.

    Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.


  • Open Access

    Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer

    by A Choughule, R Sharma, V Trivedi, A Thavamani, V Noronha, A Joshi, S Desai, P Chandrani, P Sundaram, S Utture, et al.